Watch this free webinar to learn about the biggest opportunities for the future of cancer immunotherapy.   In this free webinar, you will hear from immunologist Dr Frédéric Triebel, CSO and CMO of Immutep, two experts from DeciBio: Dr Carl Schoellhammer, Principal, and Dr Joe Daccache, Senior Life Science Expert, Veronique Baron, Scientific Applications Manager, Marketing […]

CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. In her webinar, Dr García Macía discusses how failure in autophagy causes the accumulation of structurally and bioenergetically impaired neuronal mitochondria in the mouse model of CLN7 disease, and how the mitochondrial reactive oxygen species (mROS) in Cln7 disease neurons […]

Watch this free webinar to learn about the biggest challenges and opportunities facing the NGS oncology space.   You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.  In […]

AI and machine learning (AI/ML) methods offer an alluring way to expedite the drug discovery process by delivering a large number of possible new candidates for any given therapeutic area. However, insight from medicinal chemists is still necessary to triage and prioritise the most promising molecules for synthesis, and progress these through the Design-Make-Test-Analyse (DMTA) […]

Cell and gene therapies are transforming the way diseases are treated. As research progresses it is hoped that cell and gene therapies will offer innovation for the future. In this on-demand webinar you will hear from CBO/CDO of Adthera Bio, Stuart Curbishley, Chief Executive Officer of Cell & Gene Therapy Catapult, Matthew Durdy, Founder and […]

CAR-T cell therapies are a promising approach for treating solid tumours. But identifying appropriate T-cell receptor (TCR) domains that exclusively target tumour antigens remains a challenge. Toxicity, tumour activation, and tumour persistence are significant challenges to using CAR-T cell therapies for solid tumours. In this webinar, Twist Bioscience’s CSO, Aaron Sato, will present several proof-of-concept […]

From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this biotech company is developing a first-in-class therapy for the millions of people whose daily lives are limited by food allergies and other severe allergic […]

Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. This presentation will introduce Berkeley Lights’ newest antibody discovery workflow, the Opto Memory B Discovery workflow, and share how customers are using the workflow to screen rabbit memory […]

Generation of a highly expressing, regulatory acceptable clonal cell line is the first key activity in the development of a biopharmaceutical. Cell line development is labour intensive, time consuming and costly and is subject to stringent regulations to ensure patient safety. All cell lines used to produce clinical batches of biopharmaceuticals are required to conform […]

Extensive manipulation, mechanical force, and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is identification of drug targets that are not relevant to the biological process under study. Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to Guide […]